Our team will begin the evaluation of a novel drug that is administered intrathecally. It is a phase I trial with an oligonucleotide, administered intrathecally, which aims to reduce the formation of alfasinuclein, by inhibiting the LRKK2 gene.
Related Stories
21 de noviembre de 2023
Evaluation of an inhibitor of the LRRK 2 gene in Parkinson’s patients. Oral tract. We…
21 de noviembre de 2023
Trial on LRRK2 mutation in Parkinson’s is about to be completed. Our Trials Unit is…
8 de mayo de 2023
Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with…
8 de mayo de 2023
The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in Spain. Manufactured…
22 de julio de 2020
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
8 de abril de 2020
An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija….
2 de abril de 2020
Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations….
11 de marzo de 2020
Our Unit has achieved to be activated in this outstanding project and so serious pathology….